Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer

Atalay, Esra; Şentürk, Şerif; Kayalı, Hülya Ayar

doi:10.1007/s10528-022-10325-1

Cited by 2 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wildtype IDH1 promotes the proliferation of colon cancer and renal cell carcinoma (15,16), the migration of primary GBM (17), the stemness of NSCLC (14), and the chemoresistance of melanoma, pancreatic cancer and NSCLC (14,25,26). However, the biological functions of wildtype IDH1 in tumor are still not well elucidated.…”

Section: Discussionmentioning

confidence: 99%

“…For instance, wildtype IDH1 maintains tumorigenesis of non-small cell lung cancer (NSCLC) and enhances gemcitabine chemoresistance by activating serine biosynthesis (14). Wildtype IDH1 are also tightly associated with tumor proliferation and migration (15)(16)(17). To sum up, the tumorpromoting role of wildtype IDH1 has been gradually recognized.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomas

Li,

Tao,

Lyu

et al. 2024

Preprint

View full text Add to dashboard Cite

Isocitrate dehydrogenase 1 (IDH1) mutations are discovered in most grade Ⅱ gliomas (71%-78%), grade Ⅲ gliomas (62%-78%) and secondary glioblastomas (88%), and have received lots of attention in recent years. However, the tumor-promoting role of wildtype IDH1 still need to be further investigated. In this article, we found wildtype IDH1 mRNA and protein levels were both elevated in glioma by using bioinformatic analysis, Besides, IDH1 mutation reduced the expression of wildtype IDH1 in U87-R132H cell line. Furthermore, the expression of wildtype IDH1 also increased along with the increase of clinical grades of glioma. Cell function and signaling pathways enrichment analyses were enriched in metabolic processes, phosphatase complex, TCA, DNA replication, p53 signaling pathway, Notch signaling pathway, et al. Single-cell sequencing analysis revealed that high expression of wildtype IDH1 correlated with cell cycle, metastasis, EMT, proliferation, invasion, stemness, and DNA damage. Besides, wildtype IDH1 promoted GBM cell viability, migration, and radioresistance in vitro. Wildtype IDH1 was significantly relevant with diagnosis, prognosis, and survival probability of glioma patients. Therefore, wildtype IDH1 could be an underlying target for glioma therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomas

Li,

Tao,

Lyu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Gene expression changes of isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 affect carcinogenesis and survival probability

BULUT ATALAY

2024

Gümüşhane Üniversitesi Fen Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

Isocitrate dehydrogenase (IDH) is an essential metabolic enzyme in the regulation of cellular metabolism. IDH gene encodes three protein isoforms, IDH1, IDH2, and IDH3, and the expression level of isoforms is altered in human cancer types. Examining the gene expression level of IDH is a therapeutic advantage that could help find a new target to use in cancer metabolism. The present study aimed to explore the gene expression level of IDH1 and IDH2 isoforms in the ten common human cancers using bioinformatic tools. In addition, the effect of gene expression changes on IDH1 and IDH2 on carcinogenesis and survival probability was examined in publicly available data deposited in the TCGA database. The results showed that the expression of IDH isoforms showed tissue-specific differences. IDH1 expression increased in esophageal and lung squamous cell carcinoma and lung and stomach adenocarcinoma tumors. Bladder urothelial, breast urothelial, and lung squamous cell carcinoma, colon, and lung adenocarcinoma displayed a significant upregulation of IDH2 expression. There was a direct relationship between the expression of IDH isoforms and the progression of various cancer types. High IDH1 expression led to decreased survival probability in esophageal carcinoma, lung, and stomach adenocarcinoma. Elevated IDH2 expression level led to decreased survival probability in bladder urothelial, breast urothelial, and lung squamous cell carcinoma and colon adenocarcinoma. In conclusion, all data showed that IDH1 could be a biomarker for esophageal carcinoma, lung and stomach adenocarcinoma, and IDH2 for bladder urothelial, breast urothelial, and lung squamous cell carcinoma, and colon adenocarcinoma.

show abstract

Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer

Cited by 2 publications

References 36 publications

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomas

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomas

Gene expression changes of isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 affect carcinogenesis and survival probability

Contact Info

Product

Resources

About